September 29, 2017
1 min read

FDA approves fast-acting mealtime insulin

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Bruce Bode
Bruce Bode

The FDA today approved Novo Nordisk’s insulin aspart injection, a fast-acting mealtime insulin to improve glycemic control in adults with type 1 and type 2 diabetes, according to a company press release.

The insulin aspart injection, Fiasp, is a new formulation of NovoLog that includes niacinamide, which helps increase the speed of insulin absorption. The injection should be administered before a meal or within 20 minutes of finishing a meal.

“With Fiasp, we’ve built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target,” Bruce Bode, MD, FACE, president of Atlanta Diabetes Associates and associate professor at Emory University School of Medicine, said in the release. “The intention of rapid-acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, a process that is important for optimal HbA1c management.”

Approval for the injection was based on results from a phase 3a clinical development program in which more than 2,000 adults with type 1 and type 2 diabetes were enrolled to evaluate the safety and efficacy of the fast-acting insulin administered at mealtime and after starting a meal. HbA1c was effectively reduced with the fast-acting insulin, according to the company. Nasopharyngitis, upper respiratory tract infection, nausea, diarrhea and back pain were common adverse reactions.

The injection will be available in a prefilled delivery device and a 10-mL vial.